CA2796388A1 - 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases - Google Patents

5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases Download PDF

Info

Publication number
CA2796388A1
CA2796388A1 CA2796388A CA2796388A CA2796388A1 CA 2796388 A1 CA2796388 A1 CA 2796388A1 CA 2796388 A CA2796388 A CA 2796388A CA 2796388 A CA2796388 A CA 2796388A CA 2796388 A1 CA2796388 A1 CA 2796388A1
Authority
CA
Canada
Prior art keywords
alkyl
formula
ring
membered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2796388A
Other languages
English (en)
French (fr)
Inventor
Mark Laurence Boys
Laurence E. Burgess
Robert D. Groneberg
Darren M. Harvey
Lily Huang
Timothy Kercher
Christopher F. Kraser
Ellen Laird
Eugene Tarlton
Qian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CA2796388A1 publication Critical patent/CA2796388A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2796388A 2010-04-14 2011-04-11 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases Abandoned CA2796388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32418610P 2010-04-14 2010-04-14
US61/324,186 2010-04-14
PCT/US2011/031896 WO2011130146A1 (en) 2010-04-14 2011-04-11 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Publications (1)

Publication Number Publication Date
CA2796388A1 true CA2796388A1 (en) 2011-10-20

Family

ID=43984073

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2796388A Abandoned CA2796388A1 (en) 2010-04-14 2011-04-11 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Country Status (21)

Country Link
US (1) US8962596B2 (enExample)
EP (1) EP2558468B1 (enExample)
JP (2) JP2013523884A (enExample)
KR (1) KR20130094710A (enExample)
CN (1) CN102985424B (enExample)
AR (1) AR081075A1 (enExample)
AU (1) AU2011240808B2 (enExample)
CA (1) CA2796388A1 (enExample)
CL (1) CL2012002882A1 (enExample)
CO (1) CO6630187A2 (enExample)
CR (1) CR20120572A (enExample)
MX (1) MX2012011941A (enExample)
NZ (1) NZ603446A (enExample)
PH (1) PH12012502046A1 (enExample)
RU (1) RU2012148246A (enExample)
SG (1) SG184870A1 (enExample)
TW (1) TWI494314B (enExample)
UA (1) UA109131C2 (enExample)
UY (1) UY33328A (enExample)
WO (1) WO2011130146A1 (enExample)
ZA (1) ZA201208544B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2474545T (pt) 2005-12-13 2017-02-14 Incyte Holdings Corp Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase
GEP20125533B (en) 2007-06-13 2012-05-25 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentyl propanenitrile
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
BRPI1011993A2 (pt) 2009-06-17 2021-07-06 Vertex Pharmaceuticals Incorporated inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR20140019300A (ko) 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
PH12014500730A1 (en) * 2011-10-12 2018-01-17 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
AU2012336019A1 (en) * 2011-11-07 2014-05-29 Vertex Pharmaceuticals Incorporated Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JP6196678B2 (ja) 2012-10-24 2017-09-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
BR122021015061B1 (pt) * 2013-03-06 2022-10-18 Incyte Holdings Corporation Processos e intermediários para preparar um inibidor de jak
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
EP2980089B1 (en) * 2013-03-28 2017-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
SI3786162T1 (sl) * 2013-05-17 2024-02-29 Incyte Holdings Corporation Bipirazolni derivati kot zaviralci JAK
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
BR112017011798A2 (pt) 2014-12-05 2017-12-26 Array Biopharma Inc 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
ES2962330T3 (es) 2015-01-20 2024-03-18 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de jak
KR102006684B1 (ko) * 2015-04-29 2019-08-02 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
AU2016271904B2 (en) 2015-05-29 2018-05-10 Wuxi Fortune Pharmaceutical Co.,Ltd Janus kinase inhibitor
AR104918A1 (es) * 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
ES2877200T3 (es) 2016-01-26 2021-11-16 Hangzhou Bangshun Pharmaceutical Co Ltd Derivado azacíclico de cinco miembros de pirrolopirimidina y aplicación del mismo
ME03743B (me) * 2016-02-24 2021-04-20 Pfizer Derivati pirazolo[1,5-a]pirazin-4-ila kao inhibitori jak
KR102485731B1 (ko) 2017-01-23 2023-01-05 상하이 롱우드 바이오파마슈티칼스 컴퍼니 리미티드 Jak 효소 억제제 및 이의 제조 방법과 용도
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
EP3666770A4 (en) 2017-08-07 2021-04-07 Joint Stock Company "Biocad" NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CN118490690A (zh) 2018-02-16 2024-08-16 因赛特公司 用于治疗细胞因子相关的病症的jak1通路抑制剂
PL3773593T3 (pl) 2018-03-30 2024-09-02 Incyte Corporation Leczenie ropnego zapalenia gruczołów potowych z zastosowaniem inhibitorów jak
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
JP7256291B2 (ja) * 2019-04-12 2023-04-11 プライムジーン（ベイジン）カンパニー リミテッド ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
SMT202400509T1 (it) 2020-06-02 2025-01-14 Incyte Corp Procedimenti di preparazione di un inibitore di jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
JP2024516302A (ja) 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹を治療するためのｊａｋ１経路阻害薬
EP4431510A4 (en) * 2021-11-12 2025-03-19 Soter Biopharma Pte. Ltd. Pyrazolo-fused ring compound and use thereof
JP2025515466A (ja) * 2022-04-25 2025-05-15 イーライ リリー アンド カンパニー Ｆｇｆｒ２阻害剤化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
ATE292121T1 (de) 1998-08-21 2005-04-15 Parker Hughes Inst Chinazolinderivate
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
JP2008516973A (ja) * 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
PT2474545T (pt) 2005-12-13 2017-02-14 Incyte Holdings Corp Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas com heteroarilo como inibidores de janus quinase
MY188335A (en) * 2006-11-22 2021-11-30 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EA017218B1 (ru) 2008-03-11 2012-10-30 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak-киназ
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به

Also Published As

Publication number Publication date
CN102985424B (zh) 2015-03-11
UA109131C2 (ru) 2015-07-27
EP2558468A1 (en) 2013-02-20
AU2011240808A1 (en) 2012-11-29
CL2012002882A1 (es) 2013-02-08
EP2558468B1 (en) 2015-04-01
TW201134827A (en) 2011-10-16
RU2012148246A (ru) 2014-05-20
MX2012011941A (es) 2013-08-27
WO2011130146A1 (en) 2011-10-20
JP2015205905A (ja) 2015-11-19
CO6630187A2 (es) 2013-03-01
AR081075A1 (es) 2012-06-06
UY33328A (es) 2012-10-31
JP2013523884A (ja) 2013-06-17
CN102985424A (zh) 2013-03-20
AU2011240808B2 (en) 2015-01-22
NZ603446A (en) 2014-05-30
US8962596B2 (en) 2015-02-24
PH12012502046A1 (en) 2017-07-26
US20130131039A1 (en) 2013-05-23
KR20130094710A (ko) 2013-08-26
ZA201208544B (en) 2015-04-29
CR20120572A (es) 2013-02-20
SG184870A1 (en) 2012-11-29
TWI494314B (zh) 2015-08-01

Similar Documents

Publication Publication Date Title
CA2796388A1 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
CA3171774C (en) AMINE DERIVATIVE PYRIMIDINE OR SUBSTITUTED PYRIDINE, RELATED COMPOSITION AND RELATED MEDICAL USE
JP5431319B2 (ja) ６−シクロアミノ−３−（ピリダジン−４−イル）イミダゾ［１，２−ｂ］−ピリダジンおよびこれらの誘導体、これらの調製および治療上の用途
AU2017200493B2 (en) Heterocyclyl compounds as MEK inhibitors
ES2399774T3 (es) Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
ES2537190T3 (es) Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
JP4319412B2 (ja) 治療剤としてのピラゾールピリミジン
AU2012318896A1 (en) Pyrrolopyrimidine compounds for the treatment of cancer
AU2011258005A1 (en) Heterocyclic compounds as Janus kinase inhibitors
SK3842001A3 (en) Pyrrolopyrimidines as protein kinase inhibitors (revised)
PT1966202E (pt) Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
CA2671980A1 (en) Quinoxaline derivatives
KR20020084116A (ko) 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
WO2005074603A2 (en) Aminobenzoxazoles as therapeutic agents
SK3852001A3 (en) 4-Aminopyrrolopyrimidines as kinase inhibitors
RU2703273C2 (ru) Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda
JP2013523884A5 (enExample)
JP2025534917A (ja) Ｎｌｒｐ３インフラマソーム阻害剤及びその応用
JP2011529918A (ja) Ｊａｋ３阻害剤としてのピペリジン誘導体
RU2012119488A (ru) Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
WO2014155300A2 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
CA2981998A1 (en) Imidazo isoindole derivative, preparation method therefor and medical use thereof
AU2021373162B2 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
JP7769648B2 (ja) スルホンアミド化合物
CA2713324A1 (en) Pyrrolopyrazine kinase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170411